21 Feb 2026 volume spike to 16,000 at C$0.13: CRCC.CN Copland Road Capital CNQ trade signal

A sharp intraday volume spike pushed CRCC.CN stock to C$0.13 on 21 Feb 2026, with 16,000 shares trading versus a 50-day average of 407. The relative volume of 39.31x flagged higher liquidity and rapid price discovery for Copland Road Capital Corporation (CNQ) during market hours. Traders should note the tight intraday range C$0.125–C$0.13, the year high C$0.20 and the company’s small market cap of C$1,438,905, which can amplify moves in either direction.

CRCC.CN stock: volume spike and intraday action

The volume spike to 16,000 shares drove a clear intraday signal for CRCC.CN stock. Average volume is 407, so today’s trade shows unusual interest. Price opened at C$0.13, hit a low of C$0.125 and a high of C$0.13. The high relative volume suggests short-term traders are testing liquidity rather than long-term accumulation.

CRCC.CN stock fundamentals and valuation

Copland Road Capital Corporation (CRCC.CN) operates in the Healthcare sector with a focus on cannabis investments. Reported EPS is -0.05 and the trailing PE is -2.60, reflecting negative earnings. Market cap stands at C$1,438,905 with 11,068,500 shares outstanding. Book value per share is C$0.05 and cash per share is C$0.03, while the current ratio is 15.37, indicating a strong short-term liquidity position on the balance sheet.

Technical setup and price levels for CRCC.CN stock

Short-term technicals show a tight band between the 50-day average C$0.14 and the 200-day average C$0.17. Immediate support sits near C$0.125 and resistance at the year high C$0.20. ADX at 100.00 signals a strong trend environment, while On-Balance Volume is negative, suggesting distribution over time. Use limit orders to enter, given thin spreads and volatile moves.

Meyka AI grade, forecast and price targets for CRCC.CN stock

Meyka AI rates CRCC.CN with a score out of 100: 63.31 / 100, Grade B, suggestion HOLD. This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly C$0.19 and yearly C$0.17. Versus the current C$0.13, the 12-month projection implies an upside of 27.10%, and the monthly target implies 46.15% upside. Forecasts are model-based projections and not guarantees.

Volume-spike trade plan and liquidity considerations for CRCC.CN stock

Given the 39.31x relative volume, traders should treat CRCC.CN stock as a short-term event trade. Suggested plan: use limit buys, set a stop at C$0.11, partial profit near C$0.17 and a full target near C$0.19. Keep position sizes small because market cap and free float are low. Watch order book depth before scaling into a trade.

Sector context and near-term catalysts for CRCC.CN stock

CRCC.CN sits in Healthcare, specifically Drug Manufacturers – Specialty & Generic, and focuses on cannabis investments. Sector pressures and regulatory updates in the U.S. drug and cannabis landscape can move the stock. Copland Road’s website lists strategic stake investments. Monitor M&A chatter, regulatory news, and any portfolio company updates for near-term catalysts source source.

Final Thoughts

CRCC.CN stock logged a notable liquidity event during market hours on 21 Feb 2026, with 16,000 shares trading at C$0.13 and a relative volume of 39.31x. That spike creates short-term trading opportunities but carries above-average risk because of the small market cap C$1,438,905 and thin float. Meyka AI’s forecast model projects C$0.17 in 12 months, implying about 27.10% upside from the current price, and a nearer-term monthly figure of C$0.19. Our Meyka AI grade of 63.31 (Grade B, HOLD) balances modest upside against weak earnings and valuation metrics such as EPS -0.05 and PE -2.60. For active traders, use tight risk controls, prefer limit orders, and size positions conservatively. For investors, wait for clearer fundamental catalysts or improved earnings before increasing exposure. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.